IQVIA (IQV) – Research Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of IQVIA (NYSE: IQV) recently:

• 7/29/2026 – IQVIA had its price target raised by Royal Bank Of Canada from $221.00 to $247.00. They now have an “outperform” rating on the stock.
• 7/29/2026 – IQVIA had its price target raised by TD Cowen from $233.00 to $288.00. They now have a “buy” rating on the stock.
• 7/29/2026 – IQVIA had its price target raised by BMO Capital Markets from $210.00 to $270.00. They now have an “outperform” rating on the stock.
• 7/29/2026 – IQVIA had its price target raised by Stifel Nicolaus from $220.00 to $276.00. They now have a “buy” rating on the stock.
• 7/29/2026 – IQVIA had its price target raised by JPMorgan Chase & Co. from $225.00 to $285.00. They now have an “overweight” rating on the stock.
• 7/29/2026 – IQVIA had its price target raised by Robert W. Baird from $252.00 to $287.00. They now have an “outperform” rating on the stock.
• 7/28/2026 – IQVIA had its “overweight” rating reaffirmed by Barclays PLC.
• 7/28/2026 – IQVIA was upgraded by William Blair to “strong-buy”.
• 7/15/2026 – IQVIA was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 7/13/2026 – IQVIA had its price target raised by Mizuho from $215.00 to $230.00. They now have an “outperform” rating on the stock.
• 7/9/2026 – IQVIA was given a new $240.00 price target by Deutsche Bank Aktiengesellschaft.
• 7/6/2026 – IQVIA had its “buy” rating reaffirmed by HSBC Holdings plc. They now have a $240.00 price target on the stock.
• 7/1/2026 – IQVIA had its price target raised by Robert W. Baird from $230.00 to $249.00. They now have an “outperform” rating on the stock.
• 6/27/2026 – IQVIA was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/17/2026 – IQVIA had its “equal weight” rating reaffirmed by Morgan Stanley. They now have a $200.00 price target on the stock, down from $225.00.
• 6/17/2026 – IQVIA had its “equal weight” rating reaffirmed by Morgan Stanley. They now have a $200.00 price target on the stock, down from $225.00.
• 6/14/2026 – IQVIA was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/6/2026 – IQVIA was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/3/2026 – IQVIA was given a new $210.00 price target by HSBC Holdings plc.

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.